Compass Pathways study finds COMP360 support differs from psychotherapy

Compass Pathways plc (Nasdaq: CMPS) has published a post-hoc analysis in the Journal of Psychopharmacology examining the nature of monitoring and support provided during treatment administration sessions in an open-label Phase 2 study of its investigational COMP360 synthetic psilocybin treatment in patients with post-traumatic stress disorder (PTSD).

The analysis found that 78% of administration sessions were spent in silence. Interactions between participants and support providers were described as minimal and non-directive, with patients linking support primarily to physical presence, reassurance, and validation. The study concluded that these interactions are distinct from conventional psychotherapy or trauma-focused psychological treatments.

Support providers in Compass trials are trained using a manualized approach, with strategies including breath and body awareness, short verbal cues, and physical proximity.

"It is incorrect to describe the treatment we are developing as psilocybin-assisted psychotherapy," said Dr. Guy Goodwin, Chief Medical Officer of Compass Pathways. "These findings reinforce that the rapid and durable symptom improvement observed in the open-label Phase 2 PTSD trial was attributable to the psilocybin drug experience."

COMP360 holds Breakthrough Therapy designation from the U.S. Food and Drug Administration for treatment-resistant depression, and has also received Innovative Licensing and Access Pathway designation in the UK for the same indication. The company is based in London with offices in New York.

You May Also Be Interested In

• Alphabet Sees FY26 Capex $195B To $205B, Saw $180B To $190B
• Digital Brands Group announces 1-for-40 reverse stock split
• Sigma Lithium faces $540,000 in fines, begins TAC talks in Brazil